FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 253 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Can Cancer Prevention Be Better Integrated into Primary Care? June 5, 2023 FDA Approves Cabozantinib for Differentiated Thyroid Cancer September 30, 2021 ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... May 19, 2021 New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Load more HOT NEWS Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma Finding New Uses for Targeted Therapies for Cancer: Updates from the... Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful...
